Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 210.39M | 192.00M | 177.91M | 172.25M | 167.51M |
| Gross Profit | -210.39M | -192.00M | -177.91M | -172.25M | -167.51M |
| SG&A Expenses | 68.90M | 63.52M | 59.62M | 51.80M | 46.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 279.30M | 255.52M | 237.52M | 224.04M | 214.05M |
| Operating Income | -279.30M | -255.52M | -237.52M | -224.04M | -214.05M |
| Income Before Tax | -238.42M | -213.83M | -199.34M | -188.77M | -182.69M |
| Income Tax Expenses | -4.09M | -446.00K | -283.00K | -170.00K | -292.00K |
| Earnings from Continuing Operations | -234.33 | -213.39 | -199.06 | -188.60 | -182.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -234.33M | -213.39M | -199.06M | -188.60M | -182.39M |
| EBIT | -279.30M | -255.52M | -237.52M | -224.04M | -214.05M |
| EBITDA | -276.74M | -252.74M | -233.68M | -220.26M | -210.51M |
| EPS Basic | -3.01 | -2.81 | -2.74 | -2.71 | -2.73 |
| Normalized Basic EPS | -1.91 | -1.76 | -1.72 | -1.71 | -1.74 |
| EPS Diluted | -3.01 | -2.81 | -2.74 | -2.71 | -2.73 |
| Normalized Diluted EPS | -1.91 | -1.76 | -1.72 | -1.71 | -1.74 |
| Average Basic Shares Outstanding | 311.58M | 303.16M | 291.24M | 279.43M | 267.56M |
| Average Diluted Shares Outstanding | 311.58M | 303.16M | 291.24M | 279.43M | 267.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |